Dashboard

CRISPR Therapeutics AG

CRSPNASDAQ

For informational purposes only. Not financial advice, not a recommendation to buy or sell any security. Standing Order is a directory and research project, not an advisory service.

Universal block

Live market data + trailing fundamentals.

Market cap$4.6B

Price$46.5452w $36.95 – $76.78

Conviction4/ 5

Revenue (TTM)$4M

Revenue growth YoY-88.9%

P/E (trailing)—

Gross margin-5360.9%

Operating margin-13408.3%

Net margin-13856.5%

52w price change+26.0%

Next earningsAug 3, 2026

Recent events

Material filings, federal awards, and regulatory activity. Impact is scored against market cap.

Jul 23
Trial initiationClinicalTrials.gov
CRISPR Therapeutics initiates Phase 1 safety trial of CTX310 for refractory dyslipidemias (NCT07491172).
Jul 22
Trial initiationClinicalTrials.gov
CRISPR Therapeutics initiates Phase 1/2 trial (NCT07549698) of CTX112 in relapsed/refractory hematologic autoimmune disease; status recruiting.
Jul 20
Trial initiationClinicalTrials.gov
CRISPR Therapeutics initiates Phase 1 safety trial NCT07491172 of CTX310 in refractory dyslipidemias (status: recruiting).
Jul 16
Trial initiationClinicalTrials.gov
CRISPR Therapeutics begins Phase 1/2 trial (NCT07549698) of CTX112 in relapsed/refractory hematologic autoimmune disease; status recruiting.
Jun 15
Trial initiationClinicalTrials.gov
CRISPR Therapeutics initiates Phase 1/2 trial (NCT07549698) of CTX112 in relapsed/refractory hematologic autoimmune disease; status recruiting.
Jun 9
Ownership changeSEC
Form 4 insider transaction filing.
Jun 9
Ownership changeSEC
SEC Form 4 insider ownership transaction filing.
Jun 9
Ownership changeSEC
Form 4 insider transaction filing.
Jun 9
Ownership changeSEC
Form 4 insider transaction filing by CRISPR Therapeutics AG.
Jun 9
Ownership changeSEC
Form 4 insider beneficial ownership change filing.
Jun 9
Ownership changeSEC
Form 4 insider transaction filing reported for CRISPR Therapeutics.
Jun 9
Ownership changeSEC
Form 4 insider transaction filing dated 2026-06-09.
Jun 9
Ownership changeSEC
Form 4 insider ownership filing
Jun 9
Ownership changeSEC
Form 4 insider transaction filing.
Jun 9
Ownership changeSEC
Form 4 insider transaction filing.
Jun 4
LeadershipSEC
8-K reports items 5.02/5.03/5.07: officer/director changes, bylaw amendments, and shareholder vote results.
Jun 2
Ownership changeSEC
Form 4 insider transaction filing for CRISPR Therapeutics AG.
Jun 2
Ownership changeSEC
Form 4 insider transaction filing by CRISPR Therapeutics AG.
Jun 2
Ownership changeSEC
Form 4 insider beneficial ownership report filed.
Jun 1
Ownership changeSEC
SEC Form 4 insider transaction filing.

Not financial advice — research and opinion only. Disclosures